Viral Vector & Plasmid DNA Manufacturing Market – Global Analysis & Forecast, 2019 – 2030

Report ID : 218  |  Region : Global

Viral vectors are used for the purpose of delivering genetic material into cells of a host organism. Whereas, plasmids are extra-chromosomal, small DNA molecules, which are available within a cell and is physically separate from the chromosomal DNA. Emergence of viral & non-viral vectors has been a pivotal aspect in the development of novel medicines & treatments. Moreover, advent of novel technologies have made it possible to artificially synthesize these products in large-scale while simultaneously maintaining product purity & traceability. Whereas, plasmid DNAs are used as raw materials for the synthesis of several viral vectors. Both viral vectors & plasmid DNAs are used in DNA vaccines formulations and gene therapy products against a broad spectrum of acquired, infectious and genetic diseases such as Malaria, HIV-AIDS, Ebola and several forms of influenza, cancer & enteric pathogens.

Rising adoption of regenerative medicines, increasing incidences & prevalence of chronic disorders, technological advancements, and growing popularity of gene therapy can be attributed to the growing demand for global viral vector & plasmid DNA manufacturing market in the coming years.

Some of the key players operating in the market are Merck KGaA, Novasep, Inc., uniQure N.V., FUJIFILM Diosynth Biotechnologies, Inc., Kaneka Eurogentec S.A. and Cobra Biologics among others.

To gather deep-rooted insights with respect to market dynamics, competitive landscape and to unlock the market potential of viral vector & plasmid DNA manufacturing, subscribe to the report by clicking and filling up the ‘Pre-book’ section.